Join the #FierceMadness!
Pick your favorite drug names in this year's tournament challenge. Read more and vote here!
Following mass immunization program halt, Dengvaxia’s marketing authorization in the Philippines has been put on hold for a year.
More than 70 mothers in the Philippines whose children were vaccinated against dengue filed a criminal complaint against government and company officials.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
As Philippines lawmakers continue probing the country's now-controversial dengue immunization program, a former president has spoken up to defend it.
Philippines' health secretary plans to ask Sanofi for a Dengvaxia refund and to sue the drugmaker amid worries about the dengue shot's safety.
On the heels of a safety warning, the Philippines' FDA ordered Sanofi to pull its Dengvaxia shot from the market.
The Philippines halted its dengue vaccination program after Sanofi flagged serious risks for recipients who'd never been infected with the virus.
Already reeling from bad news on its dengue shot, Sanofi canned its phase 3 C. diff vaccine—and the $500 million-plus in sales that might have come with it.
Here is some other vaccine news of note for the week.
Before heading offshore for a dubious herpes vaccine trial, a Southern Illinois University did such experiments on people in the U.S.
As Emergent BioSolutions pushes toward its goal of reaching $1 billion in annual revenues, the company has secured an important regulatory milestone.